Core Viewpoint - Ginkgo Bioworks has launched a cost-effective, high-throughput ADME profiling service aimed at accelerating small molecule drug discovery, with a focus on providing model-ready datasets and competitive pricing compared to international vendors [1][2][3] Company Overview - Ginkgo Bioworks is positioned as a leading platform for cell programming and biosecurity, offering integrated laboratory automation and large lab datasets to support AI model development [4] New Service Features - The new ADME profiling service is designed to enhance the drug development pipeline for small molecules, providing early access to rich ADME data that empowers researchers to prioritize candidates and train predictive models efficiently [2][6] - Key features include automated workflows, cost-effective pricing with a price match guarantee against international vendors, and rapid turnaround times to align with modern discovery cycles [6][3] Leadership Statement - Jason Kelly, co-founder and CEO of Ginkgo Bioworks, expressed confidence that the new ADME service will be transformative for drug discovery, emphasizing the company's ability to offer competitive pricing and quality through automation and scale [3]
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors